Tempus AI (NASDAQ:TEM) Stock Keeps “Buy” Rating at HC Wainwright

Tempus AI (NASDAQ:TEM – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $85.00 price objective on the stock. HC Wainwright‘s price target would indicate a potential upside of 33.61% from the company’s previous close.

Several other equities research analysts have also weighed in on TEM. Robert W. Baird upped their price objective on Tempus AI from $85.00 to $92.00 and gave the company an “outperform” rating in a research note on Tuesday, November 3rd. JPMorgan Chase & Co. raised their target price on Tempus AI from $45.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 14th. UBS Group assumed coverage on Tempus AI in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 price target on the stock. The Goldman Sachs Group assumed coverage on Tempus AI in a research note on Monday, September 21st. They issued a “neutral” rating and a $75.00 price target on the stock. Finally, Canaccord Genuity Group upped their price target on Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, October 12th. Eleven equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $79.37.

Check Out Our Latest Report on Tempus AI

Tempus AI Price Performance

Shares of Tempus AI stock opened at $63.62 on Thursday. The company has a debt-to-equity ratio of 2.70, a quick ratio of 2.48 and a current ratio of 2.61. The firm’s 50-day simple moving average is $72.87 and its 200-day simple moving average is $57.56. Tempus AI has a twelve month low of $40.77 and a twelve month high of $89.09. The firm has a market cap of $11.60 billion, a P/E ratio of -60.02 and a beta of 3.61.

Tempus AI (NASDAQ:TEM – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The business had revenue of $411.54 million for the quarter, compared to analysts’ expectations of $409.39 million. During the same quarter in the previous year, the firm posted ($0.46) earnings per share. The firm’s revenue for the quarter was up 23.1% on a year-over-year basis. As a group, research analysts expect that Tempus AI will post -1.20 EPS for the current fiscal year.

Insider Activity at Tempus AI

In other news, CAO Ryan Bartolucci sold 7,062 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total transaction of $529,650.00. Following the completion of the sale, the chief accounting officer owned 60,804 shares of the company’s stock, valued at approximately $4,560,300. This trade represents a 10.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 2,951 shares of Tempus AI stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total transaction of $221,325.00. Following the completion of the transaction, the executive vice president owned 135,189 shares of the company’s stock, valued at $10,139,175. This trade represents a 2.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 978,449 shares of company stock valued at $72,226,961. Insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Integrated Wealth Concepts LLC raised its holdings in shares of Tempus AI by 44.3% in the third quarter. Integrated Wealth Concepts LLC now owns 3,618 shares of the company’s stock valued at $296,000 after buying an additional 1,110 shares during the last quarter. Schwarz Investment Partners Inc. acquired a new position in Tempus AI during the 3rd quarter worth about $109,000. New York State Common Retirement Fund lifted its position in Tempus AI by 3.0% during the 3rd quarter. New York State Common Retirement Fund now owns 54,400 shares of the company’s stock worth $4,455,000 after buying an additional 1,600 shares in the last quarter. Allworth Financial LP grew its holdings in Tempus AI by 203.7% during the 3rd quarter. Allworth Financial LP now owns 2,542 shares of the company’s stock worth $208,000 after acquiring an additional 1,705 shares during the last quarter. Finally, Caprock Group LLC bought a new stake in Tempus AI during the 3rd quarter worth about $264,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

Further Reading

Analyst Recommendations for Tempus AI (NASDAQ:TEM)

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.